December 14, 2016 / 1:45 PM / 7 months ago

BRIEF-Concert Pharmaceuticals announces CTP-543 positive top-line phase 1 results

1 Min Read

Dec 14 (Reuters) - Concert Pharmaceuticals Inc

* Concert pharmaceuticals - phase 2A trial expected to commence in Q1 next year and topline primary outcome data expected by end of 2017

* Concert pharmaceuticals announces CTP-543 positive top-line phase 1 results

* Concert Pharmaceuticals Inc says Phase 2a clinical trial for CTP-543 is expected to begin in Q1 of 2017

* Concert pharmaceuticals - CTP-543 well-tolerated across all dose groups in study & there were no serious adverse events in subjects who received CTP-543

* Concert pharmaceuticals inc - intends to present phase 1 findings at a medical conference in 2017

* Concert pharmaceuticals-phase 2 a trial for CTP-543 is expected to commence in Q1 of next year, topline primary outcome data is expected by end of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below